Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 207

Similar articles for PubMed (Select 22164265)

1.

Syndecan-4 is essential for development of concentric myocardial hypertrophy via stretch-induced activation of the calcineurin-NFAT pathway.

Finsen AV, Lunde IG, Sjaastad I, Østli EK, Lyngra M, Jarstadmarken HO, Hasic A, Nygård S, Wilcox-Adelman SA, Goetinck PF, Lyberg T, Skrbic B, Florholmen G, Tønnessen T, Louch WE, Djurovic S, Carlson CR, Christensen G.

PLoS One. 2011;6(12):e28302. doi: 10.1371/journal.pone.0028302. Epub 2011 Dec 2.

2.

Syndecan-4 signaling via NFAT regulates extracellular matrix production and cardiac myofibroblast differentiation in response to mechanical stress.

Herum KM, Lunde IG, Skrbic B, Florholmen G, Behmen D, Sjaastad I, Carlson CR, Gomez MF, Christensen G.

J Mol Cell Cardiol. 2013 Jan;54:73-81. doi: 10.1016/j.yjmcc.2012.11.006. Epub 2012 Nov 22.

PMID:
23178899
3.

Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.

Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD.

Circ Res. 2004 Jan 9;94(1):110-8. Epub 2003 Dec 1.

4.

PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.

Jeong D, Kim JM, Cha H, Oh JG, Park J, Yun SH, Ju ES, Jeon ES, Hajjar RJ, Park WJ.

Circ Res. 2008 Mar 28;102(6):711-9. doi: 10.1161/CIRCRESAHA.107.165985. Epub 2008 Feb 7.

5.

Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.

Donaldson C, Eder S, Baker C, Aronovitz MJ, Weiss AD, Hall-Porter M, Wang F, Ackerman A, Karas RH, Molkentin JD, Patten RD.

Circ Res. 2009 Jan 30;104(2):265-75, 11p following 275. doi: 10.1161/CIRCRESAHA.108.190397. Epub 2008 Dec 12.

6.

Syndecan-4 signalling inhibits apoptosis and controls NFAT activity during myocardial damage and remodelling.

Echtermeyer F, Harendza T, Hubrich S, Lorenz A, Herzog C, Mueller M, Schmitz M, Grund A, Larmann J, Stypmann J, Schieffer B, Lichtinghagen R, Hilfiker-Kleiner D, Wollert KC, Heineke J, Theilmeier G.

Cardiovasc Res. 2011 Oct 1;92(1):123-31. doi: 10.1093/cvr/cvr149. Epub 2011 Jun 1.

7.

Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis.

Mohamed BA, Barakat AZ, Zimmermann WH, Bittner RE, Mühlfeld C, Hünlich M, Engel W, Maier LS, Adham IM.

J Mol Cell Cardiol. 2012 Oct;53(4):459-68. doi: 10.1016/j.yjmcc.2012.07.014. Epub 2012 Aug 1.

PMID:
22884543
8.

Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.

Grebe C, Klingebiel TM, Grau SP, Toischer K, Didié M, Jacobshagen C, Dullin C, Hasenfuss G, Seidler T.

Cardiovasc Res. 2011 Jun 1;90(3):521-8. doi: 10.1093/cvr/cvr023. Epub 2011 Jan 27.

10.

The Ca(v)3.2 T-type Ca(2+) channel is required for pressure overload-induced cardiac hypertrophy in mice.

Chiang CS, Huang CH, Chieng H, Chang YT, Chang D, Chen JJ, Chen YC, Chen YH, Shin HS, Campbell KP, Chen CC.

Circ Res. 2009 Feb 27;104(4):522-30. doi: 10.1161/CIRCRESAHA.108.184051. Epub 2009 Jan 2.

11.

Activation of the calcineurin/NFAT signalling cascade starts early in human hypertrophic myocardium.

Diedrichs H, Hagemeister J, Chi M, Boelck B, Müller-Ehmsen J, Schneider CA.

J Int Med Res. 2007 Nov-Dec;35(6):803-18.

PMID:
18034994
12.

Regulation of nerve growth factor in the heart: the role of the calcineurin-NFAT pathway.

Rana OR, Saygili E, Meyer C, Gemein C, Krüttgen A, Andrzejewski MG, Ludwig A, Schotten U, Schwinger RH, Weber C, Weis J, Mischke K, Rassaf T, Kelm M, Schauerte P.

J Mol Cell Cardiol. 2009 Apr;46(4):568-78. doi: 10.1016/j.yjmcc.2008.12.006. Epub 2008 Dec 25.

PMID:
19150448
13.

Cardiac anti-remodelling effect of aerobic training is associated with a reduction in the calcineurin/NFAT signalling pathway in heart failure mice.

Oliveira RS, Ferreira JC, Gomes ER, Paixão NA, Rolim NP, Medeiros A, Guatimosim S, Brum PC.

J Physiol. 2009 Aug 1;587(Pt 15):3899-910. doi: 10.1113/jphysiol.2009.173948. Epub 2009 Jun 8.

14.

Polycystin-1 activates the calcineurin/NFAT (nuclear factor of activated T-cells) signaling pathway.

Puri S, Magenheimer BS, Maser RL, Ryan EM, Zien CA, Walker DD, Wallace DP, Hempson SJ, Calvet JP.

J Biol Chem. 2004 Dec 31;279(53):55455-64. Epub 2004 Oct 5.

15.

Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling.

Liu Q, Chen Y, Auger-Messier M, Molkentin JD.

Circ Res. 2012 Apr 13;110(8):1077-86. doi: 10.1161/CIRCRESAHA.111.260729. Epub 2012 Mar 8.

16.

Na(+)/H(+) exchanger 1 directly binds to calcineurin A and activates downstream NFAT signaling, leading to cardiomyocyte hypertrophy.

Hisamitsu T, Nakamura TY, Wakabayashi S.

Mol Cell Biol. 2012 Aug;32(16):3265-80. doi: 10.1128/MCB.00145-12. Epub 2012 Jun 11.

17.

CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo.

Passier R, Zeng H, Frey N, Naya FJ, Nicol RL, McKinsey TA, Overbeek P, Richardson JA, Grant SR, Olson EN.

J Clin Invest. 2000 May;105(10):1395-406.

18.

Direct interaction and reciprocal regulation between ASK1 and calcineurin-NFAT control cardiomyocyte death and growth.

Liu Q, Wilkins BJ, Lee YJ, Ichijo H, Molkentin JD.

Mol Cell Biol. 2006 May;26(10):3785-97.

19.

Angiotensin II and norepinephrine activate specific calcineurin-dependent NFAT transcription factor isoforms in cardiomyocytes.

Lunde IG, Kvaløy H, Austbø B, Christensen G, Carlson CR.

J Appl Physiol (1985). 2011 Nov;111(5):1278-89. doi: 10.1152/japplphysiol.01383.2010. Epub 2011 Apr 7.

20.

Genetic loss of calcineurin blocks mechanical overload-induced skeletal muscle fiber type switching but not hypertrophy.

Parsons SA, Millay DP, Wilkins BJ, Bueno OF, Tsika GL, Neilson JR, Liberatore CM, Yutzey KE, Crabtree GR, Tsika RW, Molkentin JD.

J Biol Chem. 2004 Jun 18;279(25):26192-200. Epub 2004 Apr 13.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk